Americas · Regional markets · Financial Post
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levels…
Read the full article on Financial Post Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (financialpost.com)





